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Up-regulation of effector natural killer cells and 
effector memory CD8+ T cells in maintaining com-
plete molecular response after imatinib discontin-
uation in chronic myeloid leukemia 
Recently, some chronic myeloid leukemia CML  pa-
tients with a complete molecular response CMR  of at 
least 2 years were considered to have a sustained CMR 
after imatinib discontinuation. However, even if CMR 
status is attained, CML stem cells may remain, possibly 
owing to immune surveillance. To more appropriately 
identify patients who can safely discontinue imatinib, we 
compared the immunophenotypic profiles of CML pa-
tients who received imatinib and had a CMR for more 
than 2 consecutive years CMR group ; those without a 
sustained CMR under imatinib but who maintained a ma-
jor molecular response for more than 2 years 
CMR group ; those with a sustained CMR for more 
than 6 months after imatinib discontinuation STOP-IM 
group ; and healthy controls. Among the peripheral 
blood mononuclear cells, the percentages of effector 
populations of natural killer NK  cells, such as interfer-
on IFN - +CD3 CD56+
in the STOP-
CMR and control groups. Similarly, the percentages of 
effector memory populations of CD8+ T cells, such as 
IFN- +CCR7 CD45RO+CD8+ cells, were significantly 
higher in the STOP-IM and control groups than in the 
These results sug-
gest that safe discontinuation of imatinib depends in part 
